OMS / WHO experts say China’s two COVID-19 vaccines are harmless, but need more data
The two anti-COVID-19 vaccines of Chinese laboratory, Sinopharm and Sinovac, are effective and harmless. This is the claim of the experts of the World Health Organization, which is responsible for monitoring the quality of vaccines. However, the experts said that although the Chinese Laboratory’s anti-COVID-19 vaccines are harmless, more data needed to be collected to confirm its effectiveness. Strategic Advisory Group (SAGE) of the World Health Organization (WHO) met from March 22 to 25 to review the reliability and effectiveness of China’s two anti-COVID-19 vaccines. According to the report of the meeting, which was released on March 31, the experts claimed that the anti-COVID-19 vaccines of Sinopharm and Sinovac labs showed good efficacy, reliability, and harmless.
However, experts say there is still a lack of data on the effectiveness of these two vaccines for the elderly people with various ailments. Therefore, experts will recommend for having collecting as much data as possible to clarify the effectiveness of the China’s two vaccines. Please note that, the vaccines of Sinopharm and Sinovac Laboratories have been submitted to the World Health Organization for Accreditation in accordance with the Emergency Procedures (EUL). The World Health Organization is scheduled to make a decision in early April. After obtaining a license, other countries can start importing and vaccinating people. UNICEF also expects to buy the Chinese vaccine to distribute to countries in need.
Regarding the effectiveness of the Pfizer and BioNTech vaccines in humans between the ages of 12 and 15, a trial of 2,260 people showed that they were 100% effective. The Pfizer and BioNTech laboratories are continuing to test on the children from 6 months to 15 years old. While controversy over the side effects posed by the AstraZeneca vaccine was confirmed by the European Medicines Agency on March 31, but no vaccine was found to cause blood clots in the arteries. However, experts will continue to monitor further, but for now is still maintaining the license to use the vaccine.Sourced: RFI